ArticleJournal of neuro-oncology2015
A better surgical resectability of WHO grade II gliomas is independent of favorable molecular markers.
Article in Journal of neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Extent of resection in diffuse low-grade gliomas and the role of tumor molecular signature-a systematic review of the literature.Neurosurgical review · 2021Pooled it
- IDH wild-type WHO grade II diffuse low-grade gliomas. A heterogeneous family with different outcomes. Systematic review and meta-analysis.Neurosurgical review · 2020Pooled it
- Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Association of CDKN2A/B Homozygous Deletion and Extent of Resection With Survival of Patients With WHO CNS5 Grade 4 Astrocytoma.Annals of clinical and translational neurology · 2026Article
- Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.European radiology · 2024Article
- Prediction of glioma-subtypes: comparison of performance on a DL classifier using bounding box areas versus annotated tumors.BMC biomedical engineering · 2022Article
- Preoperative Radiomics Analysis of 1p/19q Status in WHO Grade II Gliomas.Frontiers in oncology · 2021Article
- Role of molecular biomarkers in glioma resection: a systematic review.Chinese neurosurgical journal · 2020Review
- Therapeutic Interventions in Adult Low-Grade Gliomas.Journal of clinical neurology (Seoul, Korea) · 2019Review
- Brain Mapping as Helpful Tool in Brain Glioma Surgical Treatment-Toward the "Perfect Surgery"?Brain sciences · 2018Article
- Awake mapping is not an additional surgical technique but an alternative philosophy in the management of low-grade glioma patients.Neurosurgical review · 2018Article
- The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis.Neuro-oncology · 2018Article
- Preoperative prediction of language function by diffusion tensor imaging.Brain informatics · 2017Article
- Surgical resection versus watchful waiting in low-grade gliomas.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Article
- Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.Journal of neuro-oncology · 2016Article
- Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis.Journal of neuro-oncology · 2016Article
- Residual Tumor Volume as Best Outcome Predictor in Low Grade Glioma - A Nine-Years Near-Randomized Survey of Surgery vs. Biopsy.Scientific reports · 2016Article
- Influence of 1p19q status and Ki67 index to predict extent of resection in WHO grade II gliomas: a virtual patient model.Journal of neuro-oncology · 2015Article
- Interrelationships between molecular subtype, anatomical location, and extent of resection in diffuse glioma: a systematic review and meta-analysis.Neuro-oncology advancesReview
- Comprehensive Analysis Reveals a 4-Gene Signature in Predicting Response to Temozolomide in Low-Grade Glioma Patients.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A higher extent of resection (EOR) in WHO grade II gliomas (GIIG) is correlated with longer survival. However, the molecular markers also feature prognostic relevance. Here, we examined whether maximal EOR was related to the genetic profile. We retrospectively investigated the predictive value of 1p19q, IDH1, 53 expression and Ki67 index for the EOR in 200 consecutive GIIGs (2007-2013). Data were modeled in a linear model. The analysis was performed with two statistical methods (arcsin-sqrt and Beta-regression model with logit link). There was no deletion 1p19q in 118 cases, codeletion 1p19q (57 cases), single deletion 1p (4 cases) or19q (16 cases). 155 patients had a mutation of IDH1. p53 was graded in 4 degrees (0:92 cases, 1:52 cases, 2:31 cases, 3:8 cases). Mean Ki67 index was 5.2 % (range 1-20 %). Mean preoperative tumor volume was 60.8 cm(3) (range 3.3-250 cm(3)) and mean EOR was 0.917 (range 0.574-1). The statistical analysis was significant for a lower EOR in patients with codeletion 1p19q (OR 0.738, p = 0.0463) and with a single deletion 19q (OR 0.641, p = 0.0168). There was no significant correlation between IDH1 or p53 and the EOR. Higher Ki67 was marginally associated with higher EOR (p = 0.0603). The study demonstrates in a large cohort of GIIG that a higher EOR is not attributable to favorable genetic markers. This original result supports maximal surgical resection as an important therapeutic factor per se to optimize prognosis, independently of the molecular pattern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.